Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults

Clinical Gastroenterology and Hepatology, Journal Year: 2021, Volume and Issue: 20(3), P. e573 - e582

Published: Feb. 21, 2021

Background & AimsMetabolic dysfunction-associated fatty liver disease (MAFLD) is a new terminology updated from non-alcoholic (NAFLD). In this study, we aim to estimate the global prevalence of MAFLD specifically in overweight and obese adults general population by performing systematic review meta-analysis through mining existing epidemiological data on disease.MethodsWe searched Medline, Embase, Web Science, Cochrane google scholar database inception November, 2020. DerSimonian-Laird random-effects model with Logit transformation was performed for analysis. Sensitivity analysis meta-regression were used explore predictors pooled statistics high heterogeneity.ResultsWe identified 116 relevant studies comprised 2,667,052 participants an estimated as 50.7% (95% CI 46.9-54.4) among overweight/obese regardless diagnostic techniques. Ultrasound most commonly technique generating rate 51.3% CI, 49.1-53.4). Male (59.0%; 95% 52.0-65.6) had significantly higher than female (47.5%; 40.7-54.5). Interestingly, rates are comparable based classical NAFLD non-NAFLD population. The comorbidities such type 2 diabetes metabolic syndrome 19.7% 12.8-29.0) 57.5% 49.9-64.8), respectively.ConclusionsMAFLD has astonishingly adults. This calls attention dedicated action primary care physicians, specialists, health policy makers public alike. Metabolic disease. We heterogeneity. respectively.

Language: Английский

---

MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach

Hepatology Research, Journal Year: 2021, Volume and Issue: 51(11), P. 1115 - 1128

Published: June 15, 2021

Metabolic associated fatty liver disease (MAFLD) partly overlaps with non-alcoholic (NAFLD). Thus, using a generalized estimating equation (GEE) approach, we aimed to investigate the difference in worsening of atherosclerotic cardiovascular (ASCVD) risk between patients MAFLD and NAFLD. We also investigated factors related two groups.We enrolled 2306 subjects (MAFLD 80.7%, NAFLD 63.4%). Subjects MAFLD/NAFLD were sub-classified into three groups: no metabolic dysfunction (non-Met NAFLD), overlapping, moderate alcohol consumption (mod-Alc MAFLD). ASCVD was estimated by non-invasive tests, including Suita score. An event defined as these scores from low-risk high-risk group. Independent for analyzed Cox regression analysis GEE.In analysis, (HR 1.08, 95% CI 1.02-1.15, p = 0.014) (20-39 g/day; HR 1.73, 1.26-2.36, 0.001) independently In subanalysis, incidence significantly lower non-Met than overlapping group 0.70, 0.50-0.98, 0.042). However, significant observed mod-Alc 1.19, 0.89-1.58, 0.235).The GEE approach demonstrates that better identifies Moreover, superiority over due presence rather consumption.

Language: Английский

---

Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease

Trends in Endocrinology and Metabolism, Journal Year: 2021, Volume and Issue: 32(7), P. 500 - 514

Published: May 8, 2021

Language: Английский

---

Association of metabolic dysfunction-associated fatty liver disease with kidney disease

Nature Reviews Nephrology, Journal Year: 2022, Volume and Issue: 18(4), P. 259 - 268

Published: Jan. 10, 2022

Language: Английский

---

Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China

The Journal of Clinical Endocrinology & Metabolism, Journal Year: 2021, Volume and Issue: 107(1), P. 88 - 97

Published: Sept. 11, 2021

Abstract Context In 2020, the terminology of metabolic dysfunction–associated fatty liver disease (MAFLD) was proposed to replace nonalcoholic (NAFLD). Objectives This work aimed investigate prevalence and incidence MAFLD evaluate its effects on incident extrahepatic diseases. Methods A total 6873 individuals, with a 4.6-year follow-up, were included in this study. Associations NAFLD diabetes, chronic kidney (CKD), cardiovascular (CVD) examined using logistic regression Cox proportional hazards models. Results The 40.3% (95% CI, 39.2%-41.5%) 46.7% 45.6%-47.9%), respectively. Additionally, 321 (4.7%) 156 (2.3%) participants had excessive alcohol consumption hepatitis B virus (HBV) infection. During follow-up period, 22.7% 21.3%-24.0%) 27.0% 25.5%-28.4%). associated higher risks diabetes (risk ratio [RR] 2.08; 95% 1.72-2.52), CKD (RR 1.64; 1.39-1.94), CVD (hazard 1.44; 1.15-1.81). Similar associations for observed. Furthermore, subgroups 2.49; 1.64-3.78) HBV infection 1.98; 1.11-3.52) diabetes. Conclusion change from did not greatly affect CKD, CVD. further identified those patients metabolically combined infection, who increased compared non–fatty liver.

Language: Английский

---

Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?

Hepatology, Journal Year: 2022, Volume and Issue: 76(5), P. 1423 - 1437

Published: April 1, 2022

Given the association of NAFLD with metabolic risks, a name change to MAFLD is proposed. We compared long-term outcomes and MAFLD.We included patients fatty liver disease (FLD) from NHANES III 2017-2018 (FLD defined as moderate severe hepatic steatosis by ultrasound for having controlled attenuation parameter ≥285 dB/m 2017-2018). was FLD without other diseases excess alcohol use. Metabolic-associated (MAFLD) dysfunction per criteria. All participants had linked mortality data through December 31, 2015.NHANES (n = 12,878): mean age 43.1 years old; 49.5% male; 20.3% FLD, 16.5% NAFLD, 18.1% MAFLD. 4328): 48.0 49.1% 36.8% 34.2% 36.3% Excellent concordance noted between diagnosis in both sets (kappa coefficient 0.83-0.94). Except components each definition (e.g., use MAFLD), no major differences clinical characteristics were noted. During up 27 follow-up (median 22.8 years), cumulative all-cause cause-specific In addition stage fibrosis, insulin resistance predictor alcohol-associated (ALD) MAFLD.MAFLD have similar profiles outcomes. The increased liver-related among driven resistance, primarily ALD.

Language: Английский

---

Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver

Journal of Clinical and Translational Hepatology, Journal Year: 2021, Volume and Issue: 10(2), P. 329 - 338

Published: Oct. 19, 2021

Nonalcoholic fatty liver disease (NAFLD) is a multisystemic clinical condition that presents with wide spectrum of extrahepatic manifestations, such as obesity, type 2 diabetes mellitus, metabolic syndrome, cardiovascular diseases, chronic kidney disease, malignancies, cognitive disorders, and polycystic ovarian syndrome. Among NAFLD patients, the most common mortality etiology followed by liver-related complications. Furthermore, severity diseases parallel to NAFLD. In practice, awareness associations concomitant major importance for initiating prompt timely screening multidisciplinary management spectrum. 2020, consensus from 22 countries redefined (dysfunction)-associated (MAFLD), which resulted in redefinition corresponding population. Although patients diagnosed MAFLD mostly overlap, populations are not identical. this review, we compared key between MAFLD.

Language: Английский

---

Non-alcoholic fatty liver disease: Definition and subtypes

Clinical and Molecular Hepatology, Journal Year: 2022, Volume and Issue: 29(Suppl), P. S5 - S16

Published: Dec. 28, 2022

Non-alcoholic fatty liver disease (NAFLD) is one of the most common diseases worldwide, with a global prevalence approximately 30%. However, NAFLD has been variously reported depending on comorbidities. The rising obesity in both adult and pediatric populations projected to consequently continue increasing prevalence. It major cause chronic including cirrhosis hepatocellular carcinoma (HCC). variety clinical phenotypes heterogeneity due complexity pathogenesis conditions its occurrence, resulting various prognoses. In this article, we briefly described basic definition classified subtypes based current knowledge field.

Language: Английский

---

MAFLD: a multisystem disease

Therapeutic Advances in Endocrinology and Metabolism, Journal Year: 2023, Volume and Issue: 14

Published: Jan. 1, 2023

Nonalcoholic fatty liver disease (NAFLD), affecting about 25% of general population and more than 50% dysmetabolic patients, is an emerging cause chronic its complications. Recently, international consensus experts proposed to rename this as 'Metabolic dysfunction-Associated Fatty Liver Disease' (MAFLD) focus on the bidirectional interplay between metabolic alterations stress need assessing independently from alcohol consumption other coexisting causes disease. The peculiarity NAFLD/MAFLD lies in presence a higher risk not only - expected liver-related events but also extrahepatic events, mostly cardiovascular cancers. Available evidence suggests that these associations are expression sharing same factors shed light ability particularly progressive form nonalcoholic/metabolic dysfunction-associated steatohepatitis act independent factor via promotion atherogenic dyslipidemia proinflammatory, profibrogenic, procoagulant systemic environment. present review summarizes available epidemiological clinical supporting concept multisystemic disease, highlights potential explanatory mechanisms underlying association disorders.

Language: Английский

---

Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease

Gut, Journal Year: 2023, Volume and Issue: unknown, P. gutjnl - 331003

Published: Oct. 31, 2023

Objective We explored clinical implications of the new definition metabolic dysfunction-associated steatotic liver disease (MASLD) by assessing its prevalence and associated cardiovascular (CVD) risk. Design From nationwide health screening data, we identified 9 775 066 adults aged 20–79 who underwent examination in 2009. Participants were categorised into four mutually exclusive groups: (1) MASLD; (2) MASLD with increased alcohol intake (MetALD); (3) other combined aetiology (the three collectively referred to as MASLD/related (SLD)); (4) no SLD. SLD was determined fatty index ≥30. The primary outcome CVD event, defined a composite myocardial infarction, ischaemic stroke, heart failure or death. Results MASLD, MetALD 27.5%, 4.4% 1.5%, respectively. A total 8 808 494 participants without prior followed up for median 12.3 years, during which 272 863 events occurred. cumulative incidence multivariable-adjusted risk higher than those (HR 1.38 (95% CI 1.37 1.39)). Multivariable-adjusted HR CI) 1.39 (1.38 1.40) 1.28 (1.26 1.30) 1.30 1.34) compared absence any these conditions. also non-alcoholic respective condition. Conclusion Over one-third Korean have bear high

Language: Английский

---